Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.

Translational lung cancer research·2026
Same author

Real-World Survival Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors.

Thoracic cancer·2026
Same author

Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.

Cancer science·2026
Same author

Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.

JAMA oncology·2026

Related Experiment Video

Updated: Dec 7, 2025

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.5K

A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.

Tomoaki Sonoda1,2, Noriko Yanagitani1, Kanako Suga3

  • 1Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Anticancer Research
|September 29, 2020
PubMed
Summary

This study introduces a novel method using two microfilters to detect and isolate both single and clustered circulating tumor cells (CTCs) from blood, aiding in cancer metastasis research.

Keywords:
Size-selective microfilterscirculating tumor cellcirculating tumor cell clusternon-small cell lung cancer

More Related Videos

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

227
Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.8K

Related Experiment Videos

Last Updated: Dec 7, 2025

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.5K
Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology
09:45

Microfluidics-based High-throughput Circulating Tumor Cell Sorting and Single-cell Sequencing Technology

Published on: November 14, 2025

227
Capture and Release of Viable Circulating Tumor Cells from Blood
08:10

Capture and Release of Viable Circulating Tumor Cells from Blood

Published on: October 28, 2016

8.8K

Area of Science:

  • Oncology
  • Biotechnology
  • Medical Diagnostics

Background:

  • Circulating tumor cells (CTCs) in clusters significantly enhance metastatic potential compared to single CTCs.
  • Current technologies struggle with accurate analysis of both single and clustered CTCs in peripheral blood.
  • Accurate detection and isolation of CTCs are crucial for understanding cancer progression and metastasis.

Purpose of the Study:

  • To develop and validate an effective strategy for detecting and isolating both single and cluster CTCs.
  • To utilize size-selective microfiltration for CTC analysis.
  • To enable more accurate assessment of CTCs in non-small cell lung cancer (NSCLC).

Main Methods:

  • Whole blood samples (5 ml) were collected from 10 patients with EGFR mutation-positive NSCLC.
  • Single and cluster CTCs were identified using microfiltration membranes with two distinct pore sizes.
  • Anti-EpCAM antibody labeling was employed in conjunction with microfiltration.

Main Results:

  • Simultaneous detection of single and cluster CTCs was achieved using the two size-selective microfilters.
  • The EGFR-L858R mutation was successfully detected in DNA from cells captured by both microfilters.
  • The method demonstrated the ability to differentiate and capture CTCs based on their aggregation state.

Conclusions:

  • The developed method effectively detects and isolates both single and cluster CTCs from whole blood.
  • This approach holds promise for advancing liquid biopsy strategies in cancer diagnostics.
  • Further development may lead to improved monitoring of treatment response and disease progression.